| Literature DB >> 34195385 |
Aminata S Koroma1, Habib I Kamara2, Francis Moses3, Mariama Bah2, Mohamed Turay2, Abdulai Kandeh2, Shekuba Kandeh2, Henry Allieu2, Anita Kargbo2, Anna MaCauley2, Mary H Hodges2, David Doledec4.
Abstract
BACKGROUND AND AIMS: In 2018, the transition to routine vitamin A supplementation (VAS) was integrated with caregivers' preparation of nutritious complementary food from local produce and confidential counseling and provision of modern contraceptives. In 2019, funding for complementary food ceased and Community Health Workers (CHWs) were trained to track defaulters, while national efforts to improve Health Management Information Systems, supply chains and reduce teenage pregnancies were intensified. We report on key indicators after these changes and in comparison, to those previously published.Entities:
Keywords: Albendazole; Sierra Leone; complementary feeding; family planning; vitamin A supplementation
Year: 2021 PMID: 34195385 PMCID: PMC8238388 DOI: 10.1002/hsr2.297
Source DB: PubMed Journal: Health Sci Rep ISSN: 2398-8835
Indicators collected during LQAS survey by the child's age group (months), health workers (HW) interviews, and program modalities by year
| Indicator collected | 2018 | 2019 | HW interview | |||||
|---|---|---|---|---|---|---|---|---|
| Coverages | 6–11 | 12‐23 | 24‐59 | 6‐11 | 12‐23 | 24‐59 | 2018 | 2019 |
| Vitamin A supplementation | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| Albendazole | ✓ | ✓ | ✓ | ✓ | ||||
| Penta 3 | ✓ | ✓ | ||||||
| Knowledge, awareness and practices | ||||||||
| Awareness that CF should start at 6 months | ✓ | ✓ | ✓ | |||||
| Minimum Dietary Diversity (MDD) | ✓ | ✓ | ✓ | |||||
| Minimal Meal Frequency (MMF) | ✓ | ✓ | ||||||
| VAS should be given every 6 months | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| Penta 3 should be given at 14 weeks | ✓ | ✓ | ||||||
| Modern Contraception | ✓ | ✓ | ||||||
| Practicing Family Planning | ✓ | ✓ | ||||||
| Status of Health Facility | ||||||||
| Availability of HWs trained on 6 MlyCP | ✓ | ✓ | ||||||
| Availability of trained and retained CHWs | ✓ | ✓ | ||||||
| Availability of HWs trained on Jadelle | ✓ | ✓ | ||||||
| Stockouts of VAS and or ALB | ✓ | ✓ | ||||||
| Stockouts of modern contraceptives | ✓ | ✓ | ||||||
| Stockouts of Child Health Cards | ✓ | |||||||
| Program Modalities | ||||||||
| Weekly IYCF demonstrations in PHUs | ✓ | ✓ | ||||||
| CHW defaulter tracing | ✓ | ✓ | ✓ | |||||
| Intensified HMIS reporting | ✓ | ✓ | ✓ | |||||
| Intensified supply chains for FP commodities | ✓ | ✓ | ✓ | |||||
FIGURE 1Sample map showing landmarks, segmentation, and randomly selected first household
FIGURE 2GPS location of villages where interviews were conducted, 2019
VAS, ALB, and Penta 3 coverage by verbal affirmation, weighted by PPS and VAS and ALB by card confirmation and age group (crude coverage), 2019
| VAS (N = 285) | ALB (N = 190) | Penta 3 (N = 95) | ||||
|---|---|---|---|---|---|---|
| Verbal | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) |
| Bo | 221 | 77.2 (68.885.6) | 156 | 80.6 (72.2‐89.0) | 72 | 76.2 (71.2‐81.2) |
| Kenema | 261 | 90.8 (85.0‐96.6) | 160 | 83.9 (76.5‐91.3) | 82 | 84.5 (76.5‐92.5) |
| Koinadugu | 240 | 84.2 (77.1‐91.3) | 157 | 83.1 (75.7‐90.5) | 83 | 89.9 (84.7‐95.1) |
| Overall | 722 | 84.2 (77.1–91.3) | 473 | 82.5 (74.8‐90.2) | 237 | 83.5 (76.9‐90.1) |
| Card | VAS | ALB | Penta 3 | |||
| n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |
| Bo | 179/263 | 68.1 (65.2‐70.1) | 108/173 | 62.4 (58.8‐66.1) | 66/89 | 74.2 (69.6‐78.8) |
| Kenema | 218/270 | 80.7 (78.3‐83.1) | 137/173 | 79.2 (76.1‐82.3) | 77/89 | 86.5 (82.8‐90.2) |
| Koinadugu | 152/259 | 58.7 (55.6‐61.7) | 100/165 | 60.6 (56.8‐64.4) | 79/86 | 91.9 (88.7‐95.0) |
| Overall | 549/792 | 69.3 (67.7‐71.0) | 345/511 | 67.5 (65.4‐69.6) | 222/264 | 84.1 (81.8‐86.4) |
| VAS, ALB coverage by verbal affirmation, card confirmation by age group | ||||||
| VAS | 6–11 months | 12‐23 months | 24‐59 months | |||
| n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |
| Verbal | 225/285 | *78.9 (77.8‐80.2) | 258/285 | *90.5 (89.5‐91.6) | 239/285 | *83.8 (82.8‐84.9) |
| Card | 172/266 | *64.7 (61.7‐67.6) | 214/265 | *80.8 (78.3‐83.2) | 163/261 | 62.5 (59.5‐65.4) |
| Albendazole | 12–23 months | 24‐59 months | ||||
| n | % (95% CI) | n | % (95% CI) | |||
| Verbal | 226/285 | 79.3 (78.3‐80.4) | 249/285 | 87.4 (86.4‐88.5) | ||
| Card | 178/264 | 67.4 (64.6‐70.3) | 167/247 | 67.6 (64.7‐70.6) | ||
Note: The weighting coverages varied by less than ±1.3% with the crude coverage. VAS coverage was significantly lower in 6–11 months old vs 12‐23 and 24‐59 months (*P < 0.001 each). VAS coverage by card confirmation was significantly higher in in Kenema vs Koinadugu (P < 0.001). ALB coverage by card confirmation was significantly higher in Kenema vs Koinadugu (P < 0.05).
FIGURE 3A, Sources of knowledge for VAS, 2019. B, Major reason for not receiving VAS, 2019
FIGURE 4A. Sources of knowledge for modern contraceptives, 2019. B, Contraceptives use among caregivers of children 6‐11 months old, 2019
Lots results by age group, 2019
| Lots | 1 | 2 | 3 | 4 | 5 | # | 1 | 2 | 3 | 4 | 5 | # | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| District | Indicator | Month | Verbal affirmation | Card confirmation | ||||||||||
| Bo | VAS | 6‐11 |
|
| 18 | 18 |
| 7 |
|
|
| 16 |
| 10 |
| 12‐23 |
|
| 19 | 19 | 18 |
|
| 15 | 15 | 17 | ||||
| 24‐59 |
|
| 15 | 17 | 18 |
|
|
|
| 18 | ||||
| ALB | 12‐23 | 16 |
| 17 | 17 |
| 3 |
|
|
|
|
| 8 | |
| 24‐59 |
| 18 | 17 | 16 | 17 |
| 16 |
|
| 17 | ||||
| Kenema | VAS | 6‐11 | 15 | 15 | 19 | 17 | 17 | 0 |
|
|
| 16 |
| 7 |
| 12‐23 | 19 | 16 | 19 | 19 | 19 | 17 | 16 | 19 | 15 | 17 | ||||
| 24‐59 | 17 | 18 | 18 | 18 | 15 |
| 18 | 17 |
|
| ||||
| ALB | 12‐23 | 15 |
| 16 | 18 | 18 | 3 | 14 |
| 17 | 15 | 15 | 4 | |
| 24‐59 | 18 |
| 19 | 18 |
| 15 |
| 17 |
|
| ||||
| Koinadugu | VAS | 6‐11 | 17 | 15 |
| 15 |
| 3 |
|
|
|
|
| 13 |
| 12‐23 | 17 | 17 | 16 | 18 | 17 |
|
|
| 15 | 15 | ||||
| 24‐59 | 18 |
| 18 | 15 | 18 |
|
|
|
|
| ||||
| ALB | 12‐23 | 16 | 14 |
| 17 |
| 2 | 14 |
|
|
|
| 8 | |
| 24‐59 | 17 | 16 | 17 | 18 | 17 |
|
|
| 14 |
| ||||
Note: Bolded lots failed to meet performance threshold for VAS (≥15 positives) or ALB (at ≥14 positives) by age group and or failed for VAS (≥45 positives) for 6–59 months or ALB (at ≥28 positives) for 12‐59 months.
Complementary feeding and family planning practices, 2019
| Complementary feeding | 6‐11 months (N = 285) | 6‐23 months (N = 570) | ||
|---|---|---|---|---|
| n | % (95% CI) | n | % (95% CI) | |
| Knew to introduce at 6 months | 180 | 63.2 (57.48‐68.84) | 352 | 61.8 (57.66‐65.81) |
| Provided 3 or more food groups of 6 (MDD) | 77 | 27.0 (21.77‐32.26) | 233 | 40.9 (36.77‐44.98) |
| Provided Minimum Meal Frequency (MMF) | 246 | 86.3 (82.21‐90.42) | 483 | 84.7 (81.72‐87.76) |
| Using modern contraceptives | 117 | 44.5% (41.5–47.5) | ||
Note: Contraceptives use was significantly higher in Bo and Kenema vs Koinadugu (P < 0.05).
MMF defined as 2 or more times a day for children 6‐11 months and 3 or more times a day for 12‐23 months of age.
Missing responses 22.
A summary of statistically significant findings in the LQAS 2019 vs LQAS 2018
| 2019 | 2018 |
| |
|---|---|---|---|
| Coverages | |||
| Failed VAS lots by verbal (45) | 10 | 2 | <0.05 |
| District level VAS coverage in Bo | 77.5% | 92.3% | <0.05 |
| VAS static venue 12‐23 months | 80.9% | 63.7% | <0.05 |
| VAS static venue 24‐59 months | 72.8% | 48.2% | <0.0005 |
| HMIS reports for VAS | 71.9% | 55.9% | <0.0001 |
| Knowledge awareness and practices | |||
| VAS should be every 6 months | 27.0% | 50.2% | <0.0001 |
| Penta 3 should be given at 14 weeks | 7.4% | 19.6% | <0.0001 |
| Complementary feeding | |||
| Knowledge of introduction of CF at 6 months | 63.2% | 77.2% | <0.05 |
| Minimal Dietary Diversity in children 6–11 months old | 27.0% | 44.9% | <0.0005 |
| Family planning | |||
| Information from a friend | 14.5% | 9,1% | <0.005 |
| Believe country rope an effective contraceptive | 10.5% | 20.6% | <0.005 |
| Using modern contraception | 44.5% | 37.5% | <0.05 |
| Supply chain management | |||
| Cost of FP commodities in SL Leones | 5000‐25 000 | 4000‐10 000 | |
| Stock outs contraceptives | 1.2%‐24.1% | 10.4%‐54.9% | <0.001 |
| Stock‐outs Jadelle hormonal implants | 0% | 27.0% | <0.0001 |